Medtronic gives $3.75m helping hand to NanoCor:
This article was originally published in Clinica
Medtronic has invested $3.75m in gene therapy start-up NanoCor Therapeutics to allow the latter to develop a treatment for congestive heart failure (CHF). NanoCor is aiming to use a genetically-engineered virus, developed using NanoCor-affiliate AskBio's Biological NanoParticle and self-complementary vector technologies, as a way of delivering drugs to failing heart muscles. If preclinical tests of the technology are successful, Medtronic has agreed to invest a further $3.75m. In return, Medtronic gains certain exclusive rights to licence the therapeutic, and rights to develop AskBio's technologies for the treatment of diseases of the central nervous system. Chapel Hill, North Carolina-based NanoCor will also use the new capital to hire six employees to join sole member of staff CEO Sheila Mikhail.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.